老年2型糖尿病相关风险因素与骨密度及骨折风险的关系研究

doi:10.3969/j.issn.1003-9198.2024.09.012

摘要/Abstract

摘要： 目的探讨老年T2DM人群的相关风险因素与骨密度(bone mineral density, BMD)以及骨折风险之间的关系。方法收集307例老年T2DM病人的相关临床指标和BMD,计算10年主要骨质疏松性骨折发生概率(probability of a major osteoporotic fracture, PMOF)和10年髋部骨折发生概率(probability of a hip fracture, PHF),分析糖尿病相关因素如病程、胰岛素水平、C-肽水平、用药情况与BMD和骨折发生风险之间的关系。结果 T2DM病人的BMD随着病程的延长未有明显变化(P>0.05),但PMOF和PHF明显增高(P_trend<0.05)。注射胰岛素组的T2DM病人第1、3、4腰椎以及股骨颈的BMD均高于口服降糖药物组(P<0.05),但2组间PMOF和PHF差异无统计学意义(P>0.05)。胰岛素和C-肽水平按四分位分组后发现,随着血清中胰岛素、C肽水平升高,第1～2腰椎以及股骨颈BMD呈逐渐增高的趋势(P_trend<0.05),但PMOF和PHF差异无统计学意义(P>0.05)。线性回归方程发现,第1腰椎的BMD与胰岛素水平、降糖方式呈正相关;与神经病变、低血糖发生率呈负相关(P<0.05)。PMOF和PHF与低血糖发生率、血管病变呈正相关(P<0.05)。结论 T2DM的相关因素与病人的BMD和骨折风险关系复杂,BMD水平与胰岛素的应用相关,而骨折风险却随着糖尿病病程、并发症、低血糖的发生而增加,因此需要筛查出糖尿病病人的骨折高风险人群,予以合适的治疗。

关键词: 骨折风险, 骨密度, 2型糖尿病, 并发症

Abstract: Objective To investigate the relationship of type 2 diabetes mellitus (T2DM)-related factors with bone mineral density (BMD) and fracture risk in the elderly T2DM patients. Methods The clinical data of 307 elderly patients with T2DM were collected. The 10-year probability of a major osteoporotic fracture (PMOF) and the 10-year probability of a hip fracture(PHF) were estimated using Fracture Risk Assessment Tool (FRAX). The relationship of T2DM-related factors such as disease duration, the levels of insulin and C-peptide, medication usage with BMD and the risk of fracture were explored. Results With the increase of T2DM duration, BMD showed no significant change (P>0.05), while PMOF, PHF increased significantly (P_trend<0.05). The level of BMD at lumbar spine(L1, L3, L4)and femur neck(FN)in the patients receiving insulin-injection were higher than those in the patients receiving oral hypoglycemic agents. With the increase of the levels of insulin and C-peptide, the levels of BMD at L1-2 and FN showed a gradual increasing trend(P_trend<0.05), but there was no statistically significant difference in PMOF and PHF (P>0.05). In the linear regression, BMD at L1 was positively correlated with the level of insulin and insulin injection, and negatively correlated with neuropathy and hypoglycemia (P<0.05); PMOF and PHF had a positive correlation with hypoglycemia and diabetic vascular disease (P<0.05). Conclusions There is complex relationship of BMD and fracture risk with T2DM-related factors.BMD may increase with the usage of insulin, while fracture risk increases with disease duration, complication and hypoglycemia. Therefore, it is necessary to screen the high risk of fracture in the elderly patients with T2DM.

Key words: fracture risk, bone mineral density, type 2 diabetes mellitus, complication

中图分类号:

R587.2

高远, 陈华, 陈珂, 黄文龙. 老年2型糖尿病相关风险因素与骨密度及骨折风险的关系研究[J]. 实用老年医学, 2024, 38(9): 911-915.

GAO Yuan, CHEN Hua, CHEN Ke, HUANG Wenlong. Relationship of bone mineral density and fracture risk with type 2 diabetes mellitus-related factors in elderly patients[J]. Practical Geriatrics, 2024, 38(9): 911-915.

参考文献

[1] STAVROULA A P, ANDROMACHI V.Diabetes mellitus and osteoporosis[J]. Minerva Endocrinol, 2019,44(4): 333-335.
[2] ANGELA S H, JERRY R G, CHRISTOPHER P W, et al. Assessment and treatment of osteoporosis and fractures in type 2 diabetes[J]. Trends Endocrinol Metab, 2022,33(5):333-344.
[3] HOU Y, HOU X, NIE Q, et al. Association of bone turnover markers with type 2 diabetes mellitus and microvascular complications: a matched case-control study[J]. Diabetes Metab Syndr Obes, 2023, 16:1177-1192.
[4] COMPSTON J.Type 2 diabetes mellitus and bone[J]. J Intern Med, 2018, 283(2): 140-153.
[5] MARTINS J M, ARANHA P.Abnormal mineral metabolism in diabetic patients-relevance to micro-and macrovascular disease and to bone metabolic disorder[J]. J Diabetes Treat, 2018, 1: JDBT-142.
[6] LIU G, CHANG L, PAN H,et al. The role of advanced glycation end products in fracture risk assessment in postmenopausal type 2 diabetic patients[J]. Front Endocrinol: Lausanne, 2022,13:1013397.
[7] GUIDO C, FILIPPO P, DANIELA M, et al. Role of advanced glycation end-products and oxidative stress in type-2-diabetes-induced bone fragility and implications on fracture risk stratification[J]. Antioxidants: Basel, 2023, 12(4):928.
[8] KACSO A, GOIA-SOCOL M, HAZI G,et al. Effect of experimental dysglycemia on under carboxylated osteocalcin production in human primary osteoblast-like cell cultures[J]. Acta Endocrinologica-Bucharest, 2018, 14(1): 11-15.
[9] NOURAH A, ANNA N, LINDA A D. Are diabetes microvascular complications risk factors for fragility fracture?[J]. Curr Opin Endocrinol Diabetes Obes,2021,28(4): 354-359.
[10] ZHANG W, SHEN X, WAN C,et al. Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and Erk[J]. Cell Biochem Funct,2012,30:297-302.
[11] 张萌萌.中国老年学学会骨质疏松委员会-骨代谢生化指标临床应用专家共识[J]. 中国骨质疏松杂志, 2019,25 (10):1357-1372.
[12] ANGELA S, JERRY R, CHRISTOPHER P, et al. Contributors to impaired bone health in type 2 diabetes[J]. Trends Endocrinol Metab,2023, 34(1): 34-48.
[13] CHEN R D, YANG C W, ZHU Q R, et al. Comparison of the effects of metformin and thiazolidinediones on bone metabolism: a systematic review and meta-analysis[J]. Medicina: Kaunas, 2023, 59(5):904.
[14] RAJPATHAK S N, FU C, BRODOVICZ K G, et al. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes[J]. Drugs Aging, 2015, 32(4): 321-327.
[15] CORTIZO A M, SEDLINSKY C, MCCARTHY A D, et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture[J]. Euro J Pharmacol, 2006, 536(1/2): 38-46.
[16] CHRISTIAN M, RICHARD E, DOMINIQUE D P, et al. Biochemical markers of bone fragility in patients with diabetes[J]. J Clin Endocrinol Metab, 2023, dgad255.
[17] 高远,俞海燕,郭晓珍,等.在中老年人群中2型糖尿病病程和FRAX评分之间相关性分析[J].中国骨质疏松杂志,2019,25(11):34-36.
[18] WEBER D R, LONG F, ZEMEL B S, et al. Glycemic control and bone in diabetes[J]. Curr Osteoporos Rep, 2022, 20(6):379-388.